Media Coverage

Ceva gains vaccine R&D experience with new US COO


Jul 22, 2018 - Animal Pharm
By Joseph Harvey

Tyler Martin has become Ceva Santé Animale's chief operating officer of US biology operations. 


Dr Martin is now responsible for the company's US operations related to poultry and swine vaccine production.

An expert in infectious diseases and molecular biology, he has spent most of his career in biologic development and production. Ceva will be his first post in the animal health industry.

Dr Martin has led development activities of more than 100 investigational new human drug applications. This includes working on four drugs that went on to receive US or European approval. His career has seen him work at companies such as Chiron, Novartis, Valentis, Sangamo, Humabs, Dynavax Technologies, Dance Biopharm and Univac.

From 2014 until now, Dr Martin was the chairman, chief executive and president of Adjuvance Technologies – a company focused on vaccine adjuvant design and manufacturing. He also previously founded Great Plains Biotechnology, which provides consulting, investor research and incubator services for biologics companies.

Ceva's North American division is located in Lenexa, Kansas. It ships veterinary vaccines to over 70 countries. Dr Martin joins a management team that also features Ceva's North American chief executive Craig Wallace and Stephen Payan, who is chief operational officer of the company's US pharmaceutical unit.

Reprinted with permission of Animal Pharm News

Share

Search

Archive

News Releases

Inside the Corridor

KC Animal Health Blog

Investment Forum